Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25640010 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL7263734 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL436333 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL26032485 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12238318 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL13699509 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25257785 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL14671684 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12092148 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL22939187 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| WO-2023114759-A2 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | ABL1, ABL2, ALK | MEN1 2964/4885KMT2A 193/4885GAA 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.